Patents by Inventor Bruno Guy
Bruno Guy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11333031Abstract: A turbomachine rotor blade includes a radially outer end equipped with a heel, the heel being provided with at least one sealing wiper, the or each sealing wiper projecting beyond the heel along a first axis, the first axis being at ±15° with respect to a radial direction, and extending along a second axis, substantially perpendicular to the first axis, between a first upper-surface end and a second lower-surface end, the or each sealing wiper having a first upstream side and a second downstream side as well as a radially outer surface, wherein the or each sealing wiper includes a base attached to the heel and an end piece removably interlocked with the base.Type: GrantFiled: September 17, 2018Date of Patent: May 17, 2022Assignee: SAFRAN AIRCRAFT ENGINESInventors: Vijeay Patel, Pragash Douglas, Guillaume Evrard, Quentin Bruno Guy André Emile Lievoux
-
Patent number: 10895159Abstract: An assembly includes: a movable blade for a turbomachine including a tip; and a removable part including an anti-wear material, configured to be attached removably to an edge of the tip to limit wear of the tip.Type: GrantFiled: May 24, 2018Date of Patent: January 19, 2021Assignee: Safran Aircraft EnginesInventors: Vijeay Patel, Pragash Douglas, Quentin Bruno Guy Andre Emile Lievoux, Pauline Namvong
-
Publication number: 20200277872Abstract: A turbomachine rotor blade includes a radially outer end equipped with a heel, the heel being provided with at least one sealing wiper, the or each sealing wiper projecting beyond the heel along a first axis, the first axis being at ±15° with respect to a radial direction, and extending along a second axis, substantially perpendicular to the first axis, between a first upper-surface end and a second lower-surface end, the or each sealing wiper having a first upstream side and a second downstream side as well as a radially outer surface, wherein the or each sealing wiper includes a base attached to the heel and an end piece removably interlocked with the base.Type: ApplicationFiled: September 17, 2018Publication date: September 3, 2020Inventors: Vijeay PATEL, Pragash DOUGLAS, Guillaume EVRARD, Quentin Bruno Guy André Emile LIEVOUX
-
Publication number: 20180347380Abstract: The invention relates to an assembly comprising: a movable blade (100) for a turbomachine comprising a root (130), a removable part (300) comprising an anti-wear material, configured to be attached removably to an edge of the root (130) to limit wear of the root (130).Type: ApplicationFiled: May 24, 2018Publication date: December 6, 2018Applicant: Safran Aircraft EnginesInventors: Vijeay PATEL, Pragash DOUGLAS, Quentin Bruno Guy Andre Emile LIEVOUX, Pauline NAMVONG
-
Patent number: 9937252Abstract: The present invention concerns: a) an isolated peptide comprising an amino acid sequence which is at least 90% identical to the VP4 amino acid sequence of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and/or b) an isolated peptide comprising an amino acid sequence of at least 100 amino acids which is at least 90% identical to an amino acid sequence located in the last 363 C-terminal amino acids of the RNA polymerase of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and c) a Th1 adjuvant when said immunogenic composition comprises one or more of said isolated peptides.Type: GrantFiled: February 6, 2014Date of Patent: April 10, 2018Inventors: Gary McLean, Walton Ross, Sebastian Johnston, Nathan Wylie Bartlett, Bruno Guy, Yves Girerd-Chambaz, Valerie Lecouturier, Jeffrey Almond, Nicholas Glanville, Nicolas Burdin
-
Publication number: 20160095916Abstract: The present invention concerns: a) an isolated peptide comprising an amino acid sequence which is at least 90% identical to the VP4 amino acid sequence of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and/or b) an isolated peptide comprising an amino acid sequence of at least 100 amino acids which is at least 90% identical to an amino acid sequence located in the last 363 C-terminal amino acids of the RNA polymerase of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and c) a Th1 adjuvant when said immunogenic composition comprises one or more of said isolated peptides.Type: ApplicationFiled: February 6, 2014Publication date: April 7, 2016Applicants: SANOFI PASTEUR, IMPERIAL INNOVATIONS LIMITEDInventors: Gary McLean, Walton Ross, Sebastian Johnson, Nathan Bartlett, Bruno Guy, Yves Girerd-Chambaz, Valerie Lecouturier, Jeffrey Almond, Nicholas Glanville, Nicolas Burdin
-
Patent number: 9169298Abstract: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.Type: GrantFiled: October 25, 2011Date of Patent: October 27, 2015Assignees: Centers for Disease Control and PreventionInventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
-
Publication number: 20150265695Abstract: The present invention relates to vaccine compositions that are useful in a method of protecting a human subject against dengue disease.Type: ApplicationFiled: July 24, 2013Publication date: September 24, 2015Inventors: Jiansheng Yao, Yves Girerd-Chambaz, Isabelle Legastelois, Nathalie Mantel, Véronique Barban, Jean Lang, Bruno Guy
-
Publication number: 20150031857Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.Type: ApplicationFiled: August 4, 2014Publication date: January 29, 2015Inventors: Richard KINNEY, Claire Y.H. Kinney, Veronique Barban, Jean Lang, Bruno Guy
-
Patent number: 8795688Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.Type: GrantFiled: October 25, 2011Date of Patent: August 5, 2014Assignees: Sanofi Pasteur, Centers for Disease Control and PreventionInventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
-
Publication number: 20130295164Abstract: The subject of the invention is a method for adjuvanting LPS of a Gram-negative bacterium, according to which LPS or LPS liposomes (LPS formulated in liposomes) is (are) mixed with the lipidated human-transferrin receptor subunit B (TbpB protein) of Neisseria meningitidis or a lipidated fragment thereof or (ii) LPS and the lipidated TbpB of N. meningitidis or a lipidated fragment thereof are formulated together in liposomes; or (iii) LPS is conjugated with the lipidated TbpB of N. meningitidis or a lipidated fragment thereof in order to obtain a preparation which does not contain OMVs and which is capable of inducing, after administration to a mammal, an anti-LPS immune response which is improved by comparison with the anti-LPS immune response observed after administration of the corresponding preparation in which the lipidated TbpB of N. meningitidis or a lipidated fragment thereof is omitted; as well as vaccine compositions thereof.Type: ApplicationFiled: July 12, 2013Publication date: November 7, 2013Inventors: Jean Haensler, Bruno Guy
-
Patent number: 8506971Abstract: The subject of the invention is a method for adjuvanting LPS of a Gram-negative bacterium, according to which LPS or LPS liposomes (LPS formulated in liposomes) is (are) mixed with the lipidated human-transferrin receptor subunit B (TbpB protein) of Neisseria meningitidis or a lipidated fragment thereof; or (ii) LPS and the lipidated TbpB of N. meningitidis or a lipidated fragment thereof are formulated together in liposomes; or (iii) LPS is conjugated with the lipidated TbpB of N. meningitidis or a lipidated fragment thereof; in order to obtain a preparation which does not contain OMVs and which is capable of inducing, after administration to a mammal, an anti-LPS immune response which is improved by comparison with the anti-LPS immune response observed after administration of the corresponding preparation in which the lipidated TbpB of N. meningitidis or a lipidated fragment thereof is omitted; as well as vaccine compositions thereof.Type: GrantFiled: May 14, 2010Date of Patent: August 13, 2013Assignee: Sanofi Pasteur S.A.Inventors: Jean Haensler, Bruno Guy
-
Publication number: 20120156281Abstract: The invention relates to a vaccine against N. meningitidis infections, comprising (i) an N. meningitidis LOS especially consisting of a lipid A, an inner core, and an L8-type ? chain in which the heptose II residue of the inner core (a) carries a phosphoethanolamine (PEA) substituent in position O-3, and does not carry a PEA substituent in positions O-6 and O-7, or (b) carries a phosphoethanolamine (PEA) substituent in position O-3 and in position O-6 or O-7; and (ii) the lipidated sub-unit B (TbpB) of the receptor of the human transferrine of an N. meningitidis strain or a lipid fragment of said TbpB.Type: ApplicationFiled: May 12, 2010Publication date: June 21, 2012Applicant: SANOFI PASTEURInventors: Jean Haensler, Bruno Guy, Noëlle Mistretta, Monique Moreau, Geneviève Renauld-Mongenie, Bachra Rokbi
-
Publication number: 20120083584Abstract: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.Type: ApplicationFiled: October 25, 2011Publication date: April 5, 2012Inventors: Richard KINNEY, Claire Y.H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
-
Publication number: 20120083585Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.Type: ApplicationFiled: October 25, 2011Publication date: April 5, 2012Inventors: Richard KINNEY, Claire Y.H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
-
Patent number: 8067565Abstract: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.Type: GrantFiled: December 8, 2009Date of Patent: November 29, 2011Assignees: Sanofi Pasteur, Centers For Disease Control and PreventionInventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
-
Patent number: 8067566Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.Type: GrantFiled: December 8, 2009Date of Patent: November 29, 2011Assignees: Sanofi Pasteur, Centers for Disease Control and PreventionInventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
-
Publication number: 20110014272Abstract: The subject of the invention is a method for adjuvanting LPS of a Gram-negative bacterium, according to which LPS or LPS liposomes (LPS formulated in liposomes) is (are) mixed with the lipidated human-transferrin receptor subunit B (TbpB protein) of Neisseria meningitidis or a lipidated fragment thereof; or (ii) LPS and the lipidated TbpB of N. meningitidis or a lipidated fragment thereof are formulated together in liposomes; or (iii) LPS is conjugated with the lipidated TbpB of N. meningitidis or a lipidated fragment thereof; in order to obtain a preparation which does not contain OMVs and which is capable of inducing, after administration to a mammal, an anti-LPS immune response which is improved by comparison with the anti-LPS immune response observed after administration of the corresponding preparation in which the lipidated TbpB of N. meningitidis or a lipidated fragment thereof is omitted; as well as vaccine compositions thereof.Type: ApplicationFiled: May 14, 2010Publication date: January 20, 2011Applicant: SANOFI PASTEURInventors: Jean Haensler, Bruno Guy
-
Publication number: 20100270202Abstract: The invention relates to a method for inducing a protection against the 4 dengue serotypes in a patient, comprising (a) a first series of administrations (i) of a dose of a vaccinal dengue virus of a first serotype and of a dose of a vaccinal dengue virus of a second serotype, and (ii) of a dose of a vaccinal dengue virus of a third serotype and of a dose of a vaccinal dengue virus of a fourth serotype, and (b) a second series of administrations of doses (i) and (ii), in which the doses (i) and (ii) are administered simultaneously at separate anatomical sites, and in which the second series (b) is implemented at least 30 days to at most 12 months after the first series (a).Type: ApplicationFiled: March 5, 2010Publication date: October 28, 2010Applicant: SANOFI PASTEUR SAInventors: Bruno Guy, Rémi Forrat, Jean Lang, Véronique Barban
-
Publication number: 20100239612Abstract: The invention relates to a method for inducing protection against the 4 serotypes of dengue fever in a patient, comprising: (a) the administration of a monovalent vaccine comprising a vaccinal virus of a first serotype of dengue fever, and (b) the administration of a tetravalent vaccine comprising vaccinal viruses of the four serotypes of dengue fever, in which administration (b) is made between at least 30 days and not more than 12 months following the first administration (a).Type: ApplicationFiled: March 5, 2010Publication date: September 23, 2010Applicant: SANOFI PASTEUR SAInventors: Bruno Guy, Veronique Barban, Remi Forrat, Jean Lang